Replies to post #140523 on Biotech Values

[DewDiligence]

I'd make a wager than lambda does as well as or better (gets >=$) in 2017 than the 80% of the DAAs still in trials right now.

To make your contention more meaningful, compare Lambda’s sales in 2017 to the top quintile of DAA’s that have been on the market for a minimum of, say, one year. As actually stated, your contention is almost trivially true insofar as many DAA’s in clinical trials today will never be approved.